---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-22-000020"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T00:48:11.179638+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Moderna Q1 revenue $6.1B, net income $3.7B; reiterates $21B 2022 APAs

## Summary
- GAAP diluted EPS of $8.58 vs $2.84 YoY; revenue tripled to $6.1B from $1.9B.
- Cost of sales 17% of product sales; R&D $554M, SG&A $268M.
- Cash, equivalents, and investments $19.3B at quarter end; operating cash flow $2.8B.
- Four programs in Phase 3 in Q2: Omicron bivalent COVID booster, flu, RSV, CMV.
- CFO David Meline retiring; Jorge Gomez appointed CFO effective May 9, 2022.

## SEC filing metadata
- accession: 0001682852-22-000020
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285222000020/0001682852-22-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285222000020/mrna-20220504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-22-000020
- JSON: https://secwatch.observer/filing/0001682852-22-000020.json
- Plain text: https://secwatch.observer/filing/0001682852-22-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.